Categories: Financial Results

Near 8-fold jump in Dr Reddy’s Q1 profit

Hyderabad, July 26, 2018: Pharma major Dr Reddy’s Laboratories’ consolidated net profit increased to 456 crore in the first quarter ended June 30, 2018, compared with 59 crore in the same period last year as per the International Financial Reporting Standards.

The revenue has gone up by 12 per cent to 3,721 crore, its Chief Financial Officer Saumen Chakraborti told newspersons here on Thursday.

“The contribution from generic Suboxone in the US market, forex gain and operative leverage of manufacturing drove growth,’’ he said, adding that the business was in the “right direction”.

G V Prasad, Chairman and Chief Executive Officer, said focus on operational efficiencies had helped improve margins significantly.

As part of “organisational redesigning’’, the drug-maker identified about 150 to 200 senior employees for retrenchment, the process was on, he added. During the period under review, revenues from North America increased 10 per cent at 1,590 crore driven by contribution from new products primarily Suboxone (at about $15 million, according to market reports as company did not disclose) and partly offset by competitive pressures on some key molecules.

The revenue from emerging markets increased 16 per cent at 664 crore, while in India, it had increased 30 per cent at 607 crore. In Europe, price erosion led to 3 per cent dip in revenue according to the reports published in thehindubusinessline.com.

R&D spend

The Research & Development (R&D) expenditure in the quarter was little lower at 416 crore. “But absolute R&D spend will be at historical levels,’’ Prasad said.

As on June 30, 2018, cumulatively 112 generic filing were pending with the US Food and Drug Administration (USFDA) including 109 ANDAs and three New Drug Applications. Out of 109 ANDAs, 61 are Para IV, out of which 30 have ‘First to File’ status.

Outlook

Going forward, Dr Reddy’s will give priority to a favourable judgement in the ongoing Suboxone litigation, new products, successful resolution of issues with USFDA (on Duvvada Plant) and cost efficiencies.

The company is now waiting to hear from the US regulator after inspection of the plant.

It had to stop selling Suboxone after three days of sales in the US when it was temporarily restrained by a US court. Over margin trend is “positive’’, according to Prasad.

The Pharma Times News Bureau

Recent Posts

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

8 hours ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

1 day ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

4 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

5 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

6 days ago